Evidence map›Paper›PMID 34718685›Full record

ArticleJournal of radiation research2022

In vivo dosimetry for testicular and scalp shielding in total skin electron therapy using a radiophotoluminescence glass dosimeter.

Hiroyuki Okamoto, Kae Okuma, Hiroki Nakayama, Satoshi Nakamura, Kotaro Iijima, Takahito Chiba, Mihiro Takemori, Kyohei Fujii, Shohei Mikasa, Tetsu Nakaichi and 3 more

Open access · goldAbstract readCase Reports
In one paragraph

Article in Journal of radiation research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 5 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Hiroyuki Okamoto
Kae Okuma
Hiroki Nakayama
Satoshi Nakamura
Kotaro Iijima
Takahito Chiba
Mihiro Takemori
Kyohei Fujii
Shohei Mikasa
Tetsu Nakaichi
Ako Aikawa
Shouichi Katsuta
Hiroshi Igaki

Funding

Ministry of Education, Culture, Sports, Science and Technology 18 K15613National Cancer Center Research and Development Fund 30-A-14
6 · The paper itself

Abstract

Mycosis fungoides (MF) is a common, low-grade non-Hodgkin's lymphoma of skin-homing T lymphocytes that can be treated via skin-directed radiotherapy. Our institution has implemented total skin electron therapy (TSET) with a 4.3 m source-to-surface distance (SSD) and 6 MeV electron beams with a beam spoiler. A 35-year-old male undergoing TSET desired to avoid radiotherapy-induced hair loss and temporary infertility; therefore, leakage dose to scalp and testicles was reduced with a special radiation shield composed of stacked lead sheets. The shields for the scalp and scrotal were of 3 mm and 6 mm, respectively. To assess leakage doses, a radiophotoluminescence glass dosimeter (RPLD) was placed at every fraction. The difference dose between the measured and prescribed dose at the calibration point was 2%. The top of the head and scrotal surface exhibited 18 cGy and 10 cGy, respectively. Thus, the dose to the scrotal surface was not beyond the testicular tolerance dose of 20 cGy. Results of semen analysis two months postradiotherapy were normal. There was no hair loss during or after radiation therapy. Therefore, the RPLD is a useful in vivo dosimeter that provides technical information on radiation shielding to allow for completion of TSET without hair loss or temporary infertility.

Indexed as

In Vivo DosimetryRadiation DosimetersAdultElectronsHumansMaleScalpTestisin vivo dosimetrymycosis fungoides (MF)radiophotoluminescence glass dosimeter (RPLD)total skin electron therapy (TSET)

Identifiers

PMID34718685
PMCPMC8776692
OpenAlexW3209204598

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.